Octreotide injection for advanced neuroendocrine tumors
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial is testing an injectable medicine called octreotide for people with advanced neuroendocrine tumors of the digestive system or pancreas. It aims to see if the medicine can help control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of neuroendocrine tumor (NET) in your digestive system or pancreas that has spread.
- You have had no more than two prior cancer treatments.
- You have adequate liver and kidney function, based on blood tests.
- You have not used a short-acting octreotide injection in the last week.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, sirolimus and octreotide, for people with advanced neuroendocrine tumors in the digestive system that cannot be removed by surgery and are not making excess hormones. The goal is to see if this combination can help control the tumors.
This phase 3 trial tests a radioactive drug (177Lu-DOTATATE) against a long-acting medication (Octreotide LAR) for people with advanced neuroendocrine tumors (NETs) that have grown despite standard treatment. The study aims to see which treatment works better and is safer.
This trial tests a new drug, Ac-225 DOTATATE, in people with a type of gut or pancreas tumor (GEP-NET) that has specific proteins (SSTR) on its surface. The goal is to see if it is safe and helps shrink or slow the tumor.
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
This trial looks at how well octreotide microspheres work for people with neuroendocrine tumors that cannot be removed by surgery or have spread to other parts of the body. It aims to help doctors understand the real-world benefits of this treatment.
Hear when a new Gastrointestinal Neuroendocrine Pancreatic Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.